MIRA Pharmaceuticals, Inc.
MIRA
Positions held
Your positionsMIRA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $29.54M | Enterprise value | $21.43M | Trailing P/E | — | Forward P/E | -1.71 |
| PEG | — | Price / book | 3.62 | Beta | 1.49 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -2.2% | ROA | -129.5% | Debt / equity | — |
| Current ratio | 200.08 | Free cash flow | -$1.01M | Analyst recommendation | none | Mean target | $3.50 |
| 52w high | $2.45 | 52w low | $0.60 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$1.2M | -$1.2M | -$6.0M | -$1.1M | -$1.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$1.2M | -$1.1M | -$5.8M | -$1.3M | -$1.5M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$10.4M | -$7.9M | -$12.0M | -$7.1M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$10.5M | -$8.0M | -$8.5M | -$7.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-16 · Copper Giant Identifies Thirteen Targets Beyond the Mocoa Resource and Its Interpreted Extensions
2026-09-01 · Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard
2026-09-01 · MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
2026-08-06 · MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
2026-08-06 · MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
2026-07-30 · MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
Price (daily)
Full chart · RSI · MACD · patterns